These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 17157624)

  • 21. Positron emission tomography/computed tomography in the management of Hodgkin's disease and non-Hodgkin's lymphoma.
    Rodríguez-Vigil B; Gómez-León N; Pinilla I; Hernández-Maraver D; Coya J; Martín-Curto L
    Curr Probl Diagn Radiol; 2006; 35(4):151-63. PubMed ID: 16814002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy.
    Shih WJ; Ghesani N; Hongming Z; Alavi A; Schusper S; Mozley D
    Clin Nucl Med; 2002 Feb; 27(2):142-3. PubMed ID: 11786752
    [No Abstract]   [Full Text] [Related]  

  • 23. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma.
    Schiepers C; Filmont JE; Czernin J
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S82-8. PubMed ID: 12719922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
    Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
    Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron emission tomography for detection and staging of malignant lymphoma.
    Buchmann I; Moog F; Schirrmeister H; Reske SN
    Recent Results Cancer Res; 2000; 156():78-89. PubMed ID: 10802866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.
    Kasamon YL; Wahl RL
    Curr Opin Oncol; 2008 Mar; 20(2):206-19. PubMed ID: 18300772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in the treatment of Hodgkin's disease and malignant non-Hodgkin's lymphoma].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S88-95. PubMed ID: 12739340
    [No Abstract]   [Full Text] [Related]  

  • 28. The role of FDG-PET scanning in assessing lymphoma in 2012.
    Bodet-Milin C; Eugène T; Gastinne T; Bailly C; Le Gouill S; Dupas B; Kraeber-Bodéré F
    Diagn Interv Imaging; 2013 Feb; 94(2):158-68. PubMed ID: 23295044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of pretreatment ¹⁸F-FDG PET/CT in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma treated by radioimmunotherapy using ¹³¹I-rituximab.
    Lim I; Park JY; Kang HJ; Hwang JP; Lee SS; Kim KM; Choi TH; Yang SH; Kim BI; Choi CW; Lim SM
    Acta Haematol; 2013; 130(2):74-82. PubMed ID: 23548464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of PET in lymphoma.
    Jhanwar YS; Straus DJ
    J Nucl Med; 2006 Aug; 47(8):1326-34. PubMed ID: 16883013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy.
    Falchi L; Capello D; Palumbo B; Rauco A; Emili R; Cianciulli M; Pace R; Capparella V; Liberati F; Liberati AM
    Eur J Haematol; 2007 Nov; 79(5):455-61. PubMed ID: 17908180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (18)F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma. An analysis of 193 patient studies.
    Bucerius J; Herkel C; Joe AY; Altehoefer C; Finke J; Moser E; Reinhardt MJ
    Nuklearmedizin; 2006; 45(3):105-10; quiz N25-6. PubMed ID: 16710505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of FDG-PET in malignant lymphoma.
    Becherer A; Jaeger U; Szabo M; Kletter K
    Q J Nucl Med; 2003 Mar; 47(1):14-21. PubMed ID: 12714950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. False-positive FDG-PET findings due to bone metastasis from prostate cancer in staging of non-Hodgkin's lymphoma.
    Inoue Y; Tamaki H; Yamagami T; Iwasaki H; Nakatsuka S; Soma T
    Eur J Haematol; 2007 Jul; 79(1):88-90. PubMed ID: 17532762
    [No Abstract]   [Full Text] [Related]  

  • 37. Commentary: PET poised to alter the current paradigm for response assessment of non-Hodgkin's lymphoma.
    Guermazi A; Juweid ME
    Br J Radiol; 2006 May; 79(941):365-7. PubMed ID: 16632614
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapy in Hodgkin disease and non-Hodgkin lymphomas].
    Sréter L
    Orv Hetil; 2009 Apr; 150(14):651-5. PubMed ID: 19318337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
    Cheson BD; Fisher RI; Barrington SF; Cavalli F; Schwartz LH; Zucca E; Lister TA; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    J Clin Oncol; 2014 Sep; 32(27):3059-68. PubMed ID: 25113753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.